Edition:
United States

Tobira Therapeutics Inc (RGDO.OQ)

RGDO.OQ on NASDAQ Stock Exchange Global Market

0.00USD
--
Change (% chg)

-- (--)
Prev Close
$0.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
84,668
52-wk High
$41.32
52-wk Low
$3.78

RGDO.OQ

Chart for RGDO.OQ

About

Tobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC),... (more)

Overall

Beta: --
Market Cap(Mil.): $733.84
Shares Outstanding(Mil.): 18.82
Dividend: --
Yield (%): --

Financials

  RGDO.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -3.08 -- --
ROI: -106.13 -0.26 13.91
ROE: -146.77 -3.05 14.82

BRIEF-Pentwater Capital reports passive stake of 18.8 pct in Tobira Therapeutics

* Pentwater Capital Management Lp reports passive stake of 18.8 percent in Tobira Therapeutics inc as of september 20, 2016 - SEC filing Source text for Eikon: (http://bit.ly/2d3FltC) Further company coverage:

Sep 22 2016

Allergan to buy Tobira in push for fatty liver disease drugs

Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

Sep 20 2016

UPDATE 3-Allergan to buy Tobira in push for fatty liver disease drugs

Sept 20 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity.

Sep 20 2016

Allergan to buy Tobira in push for NASH treatments

Sept 20 Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to $1.7 billion, to gain access to its experimental therapies for a fatty liver disease called NASH.

Sep 20 2016

BRIEF-Tobira therapeutics Q2 loss per share $0.71

* Tobira therapeutics reports second quarter 2016 financial and business results

Aug 09 2016

BRIEF-Tobira Therapeutics' cenicriviroc reduces inflammation, fibrosis in animal models of chronic liver, kidney diseases

* Data from multiple animal models showed cenicriviroc displayed potent anti-inflammatory, anti-fibrotic activity in multiple organs Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 27 2016

BRIEF-Tobira Therapeutics announces publication of phase 1 study results showing Cenicriviroc safety in Cirrhotic patients

* Tobira therapeutics announces publication of phase 1 study results showing cenicriviroc safety in cirrhotic patients

May 13 2016

BRIEF-Tobira Therapeutics Q1 loss per share $0.65

* Tobira Therapeutics reports first quarter 2016 financial and business results

May 09 2016

BRIEF-Tobira Therapeutics and DONG-A ST enter into license agreements for evogliptin and cenicriviroc

* Co and DONG-A ST enter into license agreements for evogliptin and cenicriviroc

Apr 11 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €67.56 -0.03
The Medicines Company (MDCO.OQ) $39.81 --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.